All articles tagged with #cancer biomarkers
This study uses in situ single-cell chromatin tracing to map 3D genome changes during Kras-driven lung and pancreatic cancers, revealing stage-specific conformational alterations that can distinguish cancer states, identify prognostic genes, and uncover regulators like Rnf2 that influence genome architecture and tumor progression.
The FDA has launched a voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagnostic tests to help clinicians select appropriate cancer treatments for patients. The pilot program aims to reduce the risk of using poorly performing laboratory developed tests (LDTs) for oncology drug treatment decisions. The FDA will request performance information for the tests used to enroll patients into the clinical trials that support drug approval and post the minimum performance characteristics recommended for similar tests that may be used to select patients for treatment with the approved drug on the FDA website.